论文部分内容阅读
目的:观察肝动脉化疗栓塞联合回生口服液治疗原发性肝癌的疗效。方法:将本院本科2008年1月至2012年12月的86例中晚期原发性肝癌随机分为治疗组和对照组,每组各43例。治疗组使用TACE联合回生口服液;对照组单纯TACE治疗。治疗2周期后观察疗效及不良反应。结果:2组对原发性肝癌病灶疗效的有效率分别为(86.05±0.5)%和(60.47±0.5)%,2组在治疗前后KPS评分提高和稳定分别为(93.02±0.5)%和(65.12±0.5)%,治疗纽优于对照组(P<0.05)。结论:TACE联合回生口服液综合治疗,可缩小肿瘤病灶,具不良反应轻,提高患者生活质量,值得临床推广使用。
Objective: To observe the curative effect of transcatheter hepatic arterial chemoembolization combined with regenerative oral liquid in the treatment of primary liver cancer. Methods: 86 cases of advanced primary liver cancer from January 2008 to December 2012 in our hospital were randomly divided into treatment group and control group, with 43 cases in each group. The treatment group using TACE joint regenerative oral liquid; control group only TACE treatment. After 2 cycles of treatment efficacy and adverse reactions were observed. Results: The effective rates of the two groups were (86.05 ± 0.5)% and (60.47 ± 0.5)%, respectively. The KPS scores of the two groups before and after treatment were (93.02 ± 0.5)% and 65.12 ± 0.5)%, the treatment of New Zealand better than the control group (P <0.05). Conclusion: TACE combined revival oral liquid therapy can reduce tumor lesions with mild adverse reactions and improve the quality of life of patients, worthy of clinical promotion and use.